OMS906 study drug
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
C3 Glomerulopathy
Conditions
C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis
Trial Timeline
Mar 1, 2024 → Apr 1, 2026
NCT ID
NCT06209736About OMS906 study drug
OMS906 study drug is a phase 2 stage product being developed by Omeros Corporation for C3 Glomerulopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06209736. Target conditions include C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06209736 | Phase 2 | Recruiting |
| NCT06298955 | Phase 2 | Recruiting |
| NCT05889299 | Phase 1 | UNKNOWN |
Competing Products
5 competing products in C3 Glomerulopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan | Novartis | Pre-clinical | 23 |
| LNP023 | Novartis | Phase 3 | 77 |
| Avacopan + Avacopan Matching Placebo | Amgen | Phase 2 | 51 |
| ARO-C3 + Placebo | Arrowhead Pharmaceuticals | Phase 1/2 | 38 |
| BCX9930 | BioCryst Pharmaceuticals | Phase 2 | 47 |